Premium
Bimodal Therapeutic Agents Against Glioblastoma, One of the Most Lethal Forms of Cancer
Author(s) -
Couto Marcos,
Alamón Catalina,
Nievas Susana,
Perona Marina,
Dagrosa María Alejandra,
Teixidor Francesc,
Cabral Pablo,
Viñas Clara,
Cerecetto Hugo
Publication year - 2020
Publication title -
chemistry – a european journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.687
H-Index - 242
eISSN - 1521-3765
pISSN - 0947-6539
DOI - 10.1002/chem.202002963
Subject(s) - sunitinib , glioblastoma , cancer research , radiation therapy , chemotherapy , glioma , medicine , cancer , pharmacology
About 95 % of people diagnosed with glioblastoma die within five years. Glioblastoma is the most aggressive central nervous system tumour. It is necessary to make progress in the glioblastoma treatment so that advanced chemotherapy drugs or radiation therapy or, ideally, two‐in‐one hybrid systems should be implemented. Tyrosine kinase receptors–inhibitors and boron neutron capture therapy (BNCT), together, could provide a therapeutic strategy. In this work, sunitinib decorated‐carborane hybrids were prepared and biologically evaluated identifying excellent antitumoral‐ and BNCT‐agents. One of the selected hybrids was studied against glioma‐cells and found to be 4 times more cytotoxic than sunitinib and 1.7 times more effective than 10 B‐boronophenylalanine fructose complex when the cells were irradiated with neutrons.